VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
NEOGNeogen Corporation
$9.58$2.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksNEOGFinancials

Neogen Corporation (NEOG) Financials

30Y historyFree accessUpdated daily

Revenue growth remains in a contractionary phase, evidenced by a 4.4% year-over-year decline in 2026Q3 alongside a compressed gross margin of 46.9%.

NEOG Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMMay'25May'24May'23May'22May'21May'20May'19May'18May'17May'16May'15May'14May'13May'12May'11May'10May'09May'08May'07May'06May'05May'04May'03May'02May'01May'00May'99May'98May'97May'96
Sales/Revenue870.54M894.66M924.22M822.45M527.16M468.46M418.17M414.19M397.93M358.28M321.27M283.07M247.41M207.53M184.05M172.68M140.51M118.72M102.42M86.14M72.43M62.76M55.5M46.49M41.1M34.9M23.51M22.2M18.5M15.3M12.5M
Revenue Growth %-3.91%-3.2%12.37%56.02%12.53%12.03%0.96%4.09%11.07%11.52%13.5%14.42%19.22%12.76%6.58%22.9%18.35%15.92%18.9%18.92%15.42%13.08%19.38%13.12%17.77%48.41%5.91%20%20.91%22.4%6.84%
Cost of Goods Sold500.03M473.29M461.59M416.49M284.15M253.4M221.89M222.27M211.66M189.35M168.21M143.39M124.81M98.03M91.62M84.89M67.53M59.29M49.19M41.58M35.43M32.15M27.99M21.76M20.2M17.16M9.91M8.6M7.2M5.6M5M
COGS % of Revenue-52.9%49.94%50.64%53.9%54.09%53.06%53.66%53.19%52.85%52.36%50.65%50.45%47.24%49.78%49.16%48.06%49.94%48.02%48.27%48.91%51.23%50.43%46.81%49.14%49.17%42.17%38.74%38.92%36.6%40%
Gross Profit370.51M421.38M462.63M405.95M243.01M215.06M196.28M191.92M186.27M168.92M153.06M139.69M122.6M109.49M92.42M87.79M72.97M59.43M53.23M44.56M37.01M30.6M27.51M24.73M20.9M17.74M13.6M13.6M11.3M9.7M7.5M
Gross Margin %42.56%47.1%50.06%49.36%46.1%45.91%46.94%46.34%46.81%47.15%47.64%49.35%49.55%52.76%50.22%50.84%51.94%50.06%51.98%51.73%51.09%48.77%49.57%53.19%50.86%50.83%57.83%61.26%61.08%63.4%60%
Gross Profit Growth %--8.92%13.96%67.05%13%9.57%2.27%3.03%10.27%10.36%9.58%13.94%11.97%18.47%5.28%20.3%22.79%11.65%19.46%20.42%20.92%11.25%11.26%18.3%17.83%30.45%-0.01%20.35%16.49%29.33%7.14%
Operating Expenses408.42M411.96M385.21M368.44M184.4M140.89M128.76M123.83M116.08M103.98M96.68M86.57M79.21M68.79M58.69M51.96M46.1M38.95M35.21M31.06M26.2M21.83M19.97M17.94M15.4M13.47M11.23M11M9.7M8.3M7M
OpEx % of Revenue-46.05%41.68%44.8%34.98%30.07%30.79%29.9%29.17%29.02%30.09%30.58%32.02%33.15%31.89%30.09%32.81%32.8%34.38%36.06%36.17%34.79%35.98%38.59%37.47%38.61%47.78%49.55%52.43%54.25%56%
Selling, General & Admin411.74M401.96M382.76M342.4M167.35M124.64M114.01M111.02M105.22M93.59M86.79M76.99M70.88M61.01M52.05M45.13M39.84M34.39M31.57M27.76M23.21M19.11M17.07M15.03M13.15M11.63M8.69M8.5M7.6M6.4M5.3M
SG&A % of Revenue-44.93%41.41%41.63%31.74%26.61%27.26%26.8%26.44%26.12%27.01%27.2%28.65%29.4%28.28%26.14%28.35%28.97%30.83%32.23%32.05%30.44%30.77%32.32%32%33.34%36.96%38.29%41.08%41.83%42.4%
Research & Development19.8M21.09M22.48M26.04M17.05M16.25M14.75M12.8M10.86M10.38M9.89M9.58M8.33M7.78M6.64M6.83M6.26M4.55M3.64M3.29M2.99M2.73M2.89M2.91M2.25M1.84M1.6M1.6M1.4M1.3M1.2M
R&D % of Revenue-2.36%2.43%3.17%3.23%3.47%3.53%3.09%2.73%2.9%3.08%3.38%3.37%3.75%3.61%3.95%4.45%3.84%3.55%3.83%4.13%4.35%5.21%6.27%5.48%5.27%6.8%7.21%7.57%8.5%9.6%
Other Operating Expenses-1000K-9.04M-20.03M00000000000000000000000946K900K700K600K500K
Operating Income-37.91M9.42M77.43M37.52M58.62M74.17M67.52M68.09M70.19M64.94M56.39M53.12M43.39M40.71M33.74M35.84M26.88M20.49M18.02M13.5M10.8M8.77M7.54M6.79M5.5M4.26M2.36M2.6M1.6M1.4M500K
Operating Margin %-4.35%1.05%8.38%4.56%11.12%15.83%16.15%16.44%17.64%18.13%17.55%18.76%17.54%19.61%18.33%20.75%19.13%17.26%17.59%15.68%14.92%13.97%13.59%14.6%13.38%12.22%10.05%11.71%8.65%9.15%4%
Operating Income Growth %--87.83%106.39%-36%-20.97%9.84%-0.84%-2.99%8.08%15.18%6.15%22.42%6.6%20.65%-5.85%33.32%31.19%13.7%33.43%24.98%23.22%16.27%11.16%23.36%28.96%80.49%-9.12%62.5%14.29%180%-16.67%
EBITDA79.23M135.09M198.65M125.89M82.31M95.21M85.92M85.72M87.25M79.64M68.57M63.77M52.57M48.12M39.91M41.16M31.31M24.38M21.54M16.34M13.22M10.47M8.94M7.92M6.57M5.57M3.31M3.5M2.3M2M1M
EBITDA Margin %9.1%15.1%21.49%15.31%15.61%20.32%20.55%20.7%21.93%22.23%21.34%22.53%21.25%23.19%21.69%23.84%22.29%20.53%21.03%18.97%18.25%16.69%16.12%17.04%15.99%15.95%14.07%15.77%12.43%13.07%8%
EBITDA Growth %-54.3%-32%57.8%52.94%-13.55%10.81%0.23%-1.76%9.56%16.14%7.53%21.3%9.26%20.56%-3.04%31.46%28.45%13.2%31.76%23.61%26.26%17.08%12.91%20.54%18.03%68.24%-5.46%52.17%15%100%-9.09%
D&A (Non-Cash Add-back)117.14M125.67M121.23M88.38M23.69M21.04M18.4M17.62M17.06M14.69M12.18M10.65M9.18M7.41M6.17M5.33M4.43M3.89M3.52M2.84M2.42M1.7M1.4M1.14M1.07M1.3M946K900K700K600K500K
EBIT-565.74M-1.06B61.37M33.92M60.21M75.27M72.31M72.96M73.47M66.67M55.51M52.08M43.03M41.14M33.96M35.24M27.32M21.62M18.5M13.89M11.13M9M7.54M6.79M5.5M4.26M2.36M2.58M1.59M1.4M500K
Net Interest Income-60.16M-68.51M-67.03M-52.8M1.27M1.61M5.99M4.68M2.04M838K322K228K115K144K107K95K81K248K0000000000000
Interest Income2.15M3.11M6.36M3.17M1.34M1.69M5.99M4.68M2.04M838K322K228K115K144K107K95K81K248K442M000098M0000000
Interest Expense62.32M71.62M73.39M55.96M72K78K0000000000000000000000000
Other Income/Expense-590.15M-1.14B-91.73M-59.56M1.59M1.1M4.78M4.87M3.27M1.73M-873K-1.04M-360K435K224K-596K442K1.14M479K371K46K147K132K488K460K605K1.92M100K700K500K-500K
Pretax Income-628.06M-1.13B-14.3M-22.04M60.21M75.27M72.31M72.96M73.47M66.67M55.51M52.08M43.03M41.14M33.96M35.24M27.32M21.62M18.5M13.88M12.09M8.92M7.67M7.27M5.96M4.87M4.28M2.7M2.3M1.9M0
Pretax Margin %-72.15%-126.65%-1.55%-2.68%11.42%16.07%17.29%17.61%18.46%18.61%17.28%18.4%17.39%19.82%18.45%20.41%19.44%18.21%18.06%16.11%16.69%14.21%13.83%15.64%14.5%13.96%18.22%12.16%12.43%12.42%-
Income Tax-19.28M-41.07M-4.88M828K11.9M14.39M12.83M12.78M10.25M22.7M18.98M18.5M15M14.1M11.45M12.4M9.8M7.75M6.4M4.75M4.15M3M2.58M2.49M2.02M1.7M1.21M400K100K100K700K
Effective Tax Rate %3.07%3.62%34.14%-3.76%19.77%19.11%17.74%17.52%13.95%34.05%34.18%35.53%34.86%34.27%33.71%35.19%35.87%35.84%34.6%34.23%34.32%33.65%33.55%34.18%33.81%34.91%28.24%14.81%4.35%5.26%-
Net Income-608.78M-1.09B-9.42M-22.87M48.31M60.88M59.48M60.18M63.15M43.79M36.56M33.53M28.16M27.19M22.51M22.84M17.52M13.87M12.1M9.13M7.94M5.92M5.1M4.79M3.94M3.17M3.07M2.3M2.2M1.8M-200K
Net Margin %-69.93%-122.06%-1.02%-2.78%9.16%13%14.22%14.53%15.87%12.22%11.38%11.84%11.38%13.1%12.23%13.23%12.47%11.69%11.81%10.59%10.96%9.43%9.19%10.3%9.6%9.08%13.07%10.36%11.89%11.76%-1.6%
Net Income Growth %-25.45%-11491.59%58.81%-147.34%-20.65%2.37%-1.16%-4.7%44.19%19.77%9.06%19.06%3.56%20.77%-1.43%30.35%26.29%14.68%32.58%14.91%34.23%16.02%6.52%21.34%24.45%3.12%33.65%4.55%22.22%1000%-128.57%
Net Income (Continuing)-608.78M-1.09B-9.42M-22.87M48.31M60.88M59.48M60.18M63.22M43.97M36.54M33.58M28.03M27.04M22.39M22.8M17.52M13.87M12.1M9.13M7.94M5.92M5.1M4.79M3.94M3.17M3.07M2.3M2.2M1.8M-200K
Discontinued Operations0000000000000000000000000000000
Minority Interest000000000143K-37K-11K-61K66K215K333K388K00000000000000
EPS (Diluted)-2.80-5.03-0.04-0.120.450.570.560.570.600.430.360.340.280.280.240.240.190.150.140.110.090.070.060.060.060.050.050.030.030.03-0.00
EPS Growth %-25.5%-11463.22%63.75%-126.67%-21.05%1.79%-1.75%-5%39.53%19.44%5.88%21.43%0%16.67%0%26.32%26.67%7.14%27.27%19.31%41.85%14.64%1.98%0.91%14.79%3.9%40.43%5.79%9.51%--127.07%
EPS (Basic)--5.03-0.04-0.120.450.570.570.580.610.430.360.340.290.280.240.250.190.160.140.110.090.070.060.060.060.050.050.030.030.03-0.01
Diluted Shares Outstanding217.7M216.89M216.48M188.88M108.02M107.12M105.72M104.85M104.37M102.33M101M99.85M99.38M97.31M96.08M95.16M92.36M90.48M89.99M84.97M86.11M91.02M89.98M86.17M71.58M66.04M66.5M69.93M70.71M63.28M56.22M
Basic Shares Outstanding217.7M216.89M216.48M188.88M107.68M106.5M105.1M103.78M103.47M101.86M100.18M99.01M97.95M96.22M94.48M92.03M89.46M87.14M86.84M82.75M84.08M86.58M87.41M84.48M67.24M64.84M66.5M69.93M68.75M63.28M36M
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Integration-driven margin erosion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Persistent Revenue Contraction Trends

According to the most recent quarterly filings, NEOG's revenue has experienced a consistent decline, with the 2026Q3 period showing a 4.4% year-over-year contraction, suggesting that the company is struggling to achieve organic growth following the integration of the 3M Food Safety business unit.

The persistent negative growth rates across the last ten quarters indicate that the company's core diagnostic offerings are facing significant headwinds or potential customer churn. Investors should monitor whether this trend reflects a structural decline in demand or temporary disruption caused by the ongoing consolidation of acquired operations.

Structural Margin Compression Remains Evident

As reported in financial statements, NEOG's gross margin has fluctuated significantly, dropping from a peak of 50.9% in 2024Q2 to 46.9% in 2026Q3, which highlights the difficulty in maintaining premium pricing power while managing the complex cost structure of the combined diagnostic entity.

The volatility in gross margins suggests that the company is struggling to pass through increased input costs to its food safety customers. This compression warrants further investigation into whether the current manufacturing footprint is optimized for the scale required by the post-merger product portfolio.

Operating Leverage Obscured by Integration

Based on the provided income statement data, NEOG's operating income has shifted into negative territory, with 2026Q3 reporting an operating margin of -1.6%, indicating that the company is currently failing to scale its overhead efficiently relative to its gross profit generation post-merger.

The inability to maintain positive operating income suggests that SG&A expenses remain disproportionately high compared to the current revenue base. This implies that the expected synergies from the 3M transaction have yet to materialize in a way that benefits the bottom line.

Earnings Quality Impaired by Charges

As evidenced by the extreme net margin volatility, including a -122.06% TTM figure, NEOG's reported net income is heavily distorted by non-recurring charges and amortization, making it difficult for investors to assess the underlying profitability of the business without adjusting for these significant accounting items.

The massive swings in net income, such as the -612.2M loss in 2025Q4, appear to be driven by one-time merger-related accounting adjustments rather than operational performance. Analysts should focus on normalized metrics to determine if the core business can eventually generate sustainable, positive cash flow.

Integration Risks Threaten Long-term Viability

Based on the reported figures, the persistent negative EPS and revenue contraction suggest that the short-seller thesis regarding the 3M Food Safety integration may be gaining traction, as the company has yet to demonstrate a clear path to restoring historical profitability levels.

The risk remains that the acquired business was under-invested, necessitating higher-than-anticipated R&D and SG&A spending that could permanently impair the company's margin profile. Investors should be cautious of the assumption that current losses are merely temporary, as the lack of revenue growth suggests deeper operational challenges.

NEOG — Frequently Asked Questions

Quick answers to the most common questions about buying NEOG stock.

What was Neogen Corporation's (NEOG) revenue in 2025?

For fiscal year 2025, Neogen Corporation (NEOG) reported total revenue of $894.7M. This represents a 7057.3% increase compared to $12.5M in 1996.

Is Neogen Corporation (NEOG) profitable?

Neogen Corporation (NEOG) reported a net loss of $1.09B for the fiscal year ending 2025.

What is Neogen Corporation's operating profit margin?

Neogen Corporation (NEOG) reported an operating income of $9.4M, resulting in an operating profit margin of 1.1%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Neogen Corporation's gross profit and gross margin?

Neogen Corporation (NEOG) generated $421.4M in gross profit for the year, representing a gross profit margin of 47.1%. This demonstrates the company's core pricing power and production efficiency.